Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke

Acta Neurologica Scandinavica

Volumn 110, Issue 4, 2004, Pages 242-247

  Haapaniemi, E ^a   Soinne, L ^a   Syrjala M ^a   Kaste, M ^a   Tatlisumak, T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Brain infarction; Coagulation; Fibrinolysis; Recurrence; Stroke

Indexed keywords

D DIMER; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CONVALESCENCE; DEMOGRAPHY; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE;

ACUTE-PHASE REACTION; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTORS; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; CONVALESCENCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 4644285725     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2004.00304.x     Document Type: Article

References (29)

1. FEINBERG W, BRUCK D, JETER M, CORRIGAN JJ. Fibrinolysis after acute ischemic stroke. Thromb Res 1991;64:117-27.
2. YAMAZAKI M, UCHIYAMA S, MARUYAMA S. Alternations of haemostatic markers in various subtypes and phases of stroke. Blood Coag Fibrinolysis 1993;4:707-12.
3. LINDGREN A, LINDOFF C, NORRVING B, ÅSTEDT B, JOHANSSON B. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996;27:1066-71.
4. FEINBERG W, ERICKSON L, BRUCK D, KITTELSON J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke 1996;27:1296-300.
5. SMITH F, RUMLEY A, LEE A, LENG G, FOWKES F, LOWE G. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998;100:758-63.
6. JOHANSSON L, JANSSON J-H, BOMAN K, NILSSON T, STEGMAYR B, HALLMANS G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000;31:26-32.
7. NAGAO T, HAMAMOTO M, KANDA A et al. Platelet activation is not involved in acceleration of the coagulation system in acute cardioembolic stroke with nonvalvular atroal fibrillation. Stroke 1995;26:1365-8.
8. DAHL T, KONTNY F, SLAGSVOLD C et al. Lipoprotein(a), other lipoproteins and hemostatic profiles in patients with ischemic stroke: the relation to cardiogenic embolism. Cerebrovasc Dis 2000;10:110-7.
9. CATTO A, CARTER A, STICKLAND M, BAMFORD J, DAVIES J, GRANT P. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997;77:730-4.
10. CARTER A, CATTO A, GRANT P. Determinants of tPA antigen and association with coronary artery disease and acute cerebrovascular disease. Thromb Haemost 1998;80:632-6.
11. INCE B, BAYRAM C, HARMANCI H, ULUTIN T. Hemostatic markers in ischemic stroke of undetermined etiology. Thromb Res 1999;96:169-74.
12. WHO. Cerebrovascular disorders: a clinical and research classification. Geneva: World Health Organization; 1978.
13. ADAMS H, BENDIXEN B, KAPPELLE L et al. Classification of subtypes of acute ischemic stroke. Stroke 1993;24:35-41.
14. ANGLETON P, CHANDLER W, SCHMER G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101-6.
15. WILTERDINK J, EASTON D. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992;49:857-63.
16. JUHAN-VAGUE I, ALESSI M, JOLY P et al. Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis 1989;9:362-7.
17. ALTÉS A, ABELLAN M, MATEO J, AVILA A, MARTI-VILALTA J, FONTCUBERTA J. Hemostatic disturbances in acute ischemic stroke: a study of 86 patients. Acta Haematol 1995;94:10-5.
18. SCHNEIDERMAN J, SAWDEY M, KEETON M et al. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992;89:6998-7002.
19. RIDKER P, HENNEKENS C, STAMPFER M, MANSON J, VAUGHAN D. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994;343:940-3.
20. MACRO R, KITTNER S, EPSTEIN A et al. Elevated tissue plasminogen activator antigen and stroke risk. Stroke 1999;30:7-11.
21. FON E, MACKEY A, COTE R et al. Hemostatic markers in acute transient ischemic attacks. Stroke 1994;25:282-6.
22. GIROUD M, DUTRILLAUX F, LEMESLE M et al. Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different. Neurol Res 1998;20:15-8.
23. YARNELL J, SWEETNAM P, RUMLEY A, LOWE G. Lifestyle and hemostatic risk factors for ischemic heart disease. Arterioscler Thromb Vasc Biol 2000;20:271-9.
24. Group EAPS. ECAT Angina Pectoris Study: baseline association of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3,000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8-17.
25. MANSFIELD M, HEYWOOD D, GRANT P. Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:160-4.
26. WOODWARD M, LOWE G, RUMLEY A et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997;97:785-97.
27. LIP G, BLANN A, BEEVERS D. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. J Hypertens 1999;17:1203-7.
28. FEINBERG W, LESLY A, HART R et al. Markers of thrombin and platelet activity in patients with atrial fibrillation. Stroke 1999;30:2547-53.
29. LI-SAW-HEE F, BLANN A, LIP G. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000;31:828-33.